Participants in this trial will receive either the study drug, remibrutinib, in the form of a film-coated tablet taken by mouth, or a placebo. The purpose of the study is to determine if this treatment can help delay the progression of disability. During the study, individuals will be monitored over a period of time to observe how the medication affects their physical abilities and overall health.

The purpose of this study is to find out if ziltivekimab works better than placebo in reducing the risk of death from heart and blood vessel problems and preventing heart failure events such as hospital stays or urgent visits for worsening heart failure. The study will also look at other health outcomes including the combined risk of death from heart problems, heart attacks, and strokes, as well as how the treatment affects kidney function, quality of life, and inflammation levels in the body. Quality of life will be measured using questionnaires that ask about symptoms and daily activities.

During the study, participants will receive monthly injections for up to 48 months. The study will track various health events including hospitalizations for heart failure, deaths, heart attacks, strokes, and changes in heart and kidney function. Blood tests will be done to measure inflammation markers like hs-CRP and heart stress markers like NT-proBNP. Heart function will be checked using echocardiography, which is an ultrasound test that creates pictures of the heart. The study will continue until enough information has been collected to determine whether ziltivekimab is effective in helping people with this type of heart failure and inflammation.

The purpose of this study is to determine whether risankizumab is as effective as or more effective than vedolizumab for treating ulcerative colitis over a 48-week period. Participants in this study will have already tried other conventional treatments such as aminosalicylates (anti-inflammatory drugs), steroids, or immunomodulators without adequate relief of their symptoms.

During the study, participants will be randomly assigned to receive either risankizumab or vedolizumab. The study will monitor improvements in the intestinal lining through endoscopy (a procedure where a small camera is used to examine the inside of the colon) and track symptom improvement including stool frequency and rectal bleeding. This is an open-label study, meaning both the healthcare providers and participants will know which medication is being administered.

The purpose of the study is to evaluate how well lutikizumab works in reducing the symptoms of ulcerative colitis and to monitor any side effects. The study will involve both intravenous (IV) and subcutaneous (SC) forms of lutikizumab, meaning the medication will be administered either through a vein or under the skin. Participants will be monitored over a period of time to assess changes in their disease activity and any adverse events they may experience.

Throughout the study, participants will undergo regular assessments to track their progress. The study aims to determine the percentage of participants who show improvement in their condition by week 12. This includes looking at endoscopic improvement, which involves examining the inside of the colon, as well as clinical remission and response, which refer to the reduction or disappearance of symptoms. The study is expected to last for up to 52 weeks, providing valuable information on the long-term effects of lutikizumab in treating ulcerative colitis.

The purpose of the study is to see if the combination of BI 690517 and empagliflozin is more effective than empagliflozin alone in helping people with heart failure. Participants in the study will be randomly assigned to receive either the combination of BI 690517 and empagliflozin or a placebo and empagliflozin. The study will last for a period of 42 days, during which participants will take the medications orally, meaning they will swallow them in the form of tablets.

Throughout the study, researchers will monitor participants to see how the treatment affects their heart failure symptoms and overall health. The main focus will be on the time it takes for a participant to experience a serious heart-related event, such as a heart-related death or hospitalization due to heart failure. The study aims to provide valuable information on whether the new combination treatment can improve outcomes for people living with heart failure.

The treatment involves receiving either Lutikizumab or placebo through subcutaneous injection (an injection under the skin). The medication being tested is a biotechnology product that aims to reduce the signs and symptoms of moderate to severe Hidradenitis Suppurativa. The study will assess how well the treatment works in both adults and adolescents who have had inadequate results with previous treatments.

The study will measure several aspects of the condition, including reduction in the number of inflammatory bumps and draining wounds, improvement in pain levels, and changes in quality of life. The treatment period will last for several months to properly evaluate the medication’s effectiveness. Throughout the study, participants will be closely monitored to ensure their safety and to track their response to the treatment.

The study will test inclisiran, given as an injection under the skin, against placebo while participants continue taking their usual cholesterol-lowering medications. These medications include either atorvastatin (40 mg daily) or rosuvastatin (20 mg or more daily), which belong to a group of drugs called statins that help lower cholesterol levels in the blood.

During the study, which will last for 72 months, participants will receive regular injections of either inclisiran or placebo along with their daily statin medication. The researchers will monitor participants to see if the combination of treatments helps prevent serious cardiovascular events like heart attacks and strokes.

The purpose of this study is to determine if remibrutinib is more effective than teriflunomide in reducing the frequency of relapses in people with relapsing forms of MS. Participants in the study will be randomly assigned to receive either remibrutinib, teriflunomide, or a placebo, which is a substance with no active medication. The study will begin with a period where participants receive either remibrutinib or teriflunomide, followed by an extended treatment phase where all participants will receive remibrutinib. This approach helps researchers understand the long-term effects of remibrutinib on MS.

Throughout the study, participants will take the medications orally, and their health will be monitored regularly to assess the impact of the treatments. The study aims to provide valuable information on how well remibrutinib works compared to teriflunomide and to ensure the safety of participants. By participating in this study, researchers hope to find a more effective treatment option for those living with relapsing MS.

Participants in the study will be randomly assigned to receive either andexanet alfa or the standard treatment, which may include a placebo. The study will monitor the effectiveness of andexanet alfa in controlling bleeding during surgery and will also track changes in the activity of the Factor Xa inhibitors from the start of the surgery to two hours afterward. The study aims to provide valuable information on how well andexanet alfa works in real-world surgical settings.

The trial will involve a series of steps, including the administration of the treatment and careful monitoring of the patient’s condition during and after the surgery. The study is expected to continue until November 2026, with recruitment starting in December 2023. This research is important for improving the safety and effectiveness of surgeries for patients who are on Factor Xa inhibitors and need urgent medical attention.

The purpose of the study is to evaluate the safety and effectiveness of these targeted therapies. Participants will receive either one of the study medications or a placebo. The study will last for a period of up to 24 weeks, during which participants will receive regular treatments and undergo various health assessments to monitor their response to the medication. The goal is to see if these treatments can help achieve endoscopic remission, which means reducing the visible signs of inflammation in the digestive tract, and clinical remission, which involves a significant reduction in symptoms.

Throughout the study, participants will be closely monitored by healthcare professionals to ensure their safety and to gather information on how well the treatments work. This research aims to provide new insights into managing Crohn’s Disease and improving the quality of life for those affected by this condition.